All states

Telehealth · DC

Washington, DC

DC residents can now access GLP-1 medications like semaglutide and tirzepatide through telehealth. Pallas Health connects you with a board-certified provider licensed in the District of Columbia who can evaluate your eligibility over a live video visit and, if appropriate, send a prescription that ships to any address in the District in 2–3 business days — Georgetown, Capitol Hill, Columbia Heights, or anywhere else in the District.

Licensed by
District of Columbia Board of Medicine
Telehealth
Video required
Compounded semaglutide
Available
Compounded tirzepatide
Available
Medicaid
Limited coverage
Shipping
2–3 business days

How telehealth prescribing works in Washington, DC

Washington, D.C. requires a real-time (synchronous) telemedicine encounter to establish the provider-patient relationship when there has been no prior in-person visit. Under District of Columbia Board of Medicine telemedicine rules, the clinician must use real-time communication for that first evaluation, so asynchronous-only review cannot establish care in the District. Every Pallas patient in D.C. meets a clinician over live video before any prescription is issued.

The District of Columbia requires a DC-licensed provider to write any prescription for a DC resident — a license from another jurisdiction is not sufficient, because your care is treated as happening where you are located. Under District of Columbia Board of Medicine telemedicine rules (17 DCMR § 4618), a clinician who has had no prior in-person, face-to-face interaction with a patient must use real-time auditory, or real-time visual and auditory, communication for the evaluation that establishes the provider-patient relationship — asynchronous-only review cannot establish care in the District. Every Pallas provider who treats DC patients holds an active District of Columbia medical license and conducts a live video visit with the patient before any prescription is issued. GLP-1s are not controlled substances, so the District's additional controlled-substance telemedicine requirements don't apply — but our providers still conduct a complete history, screen for contraindications like personal or family history of medullary thyroid carcinoma, and follow up after initiation to monitor response and titrate the dose.

Rule changes affecting Washington, DC

  1. 2026-07-24

    Arkansas, Washington D.C., North Dakota, and South Dakota moved to video-visit-required; Kansas moved to async-eligible. The video-required list now stands at 8 jurisdictions (7 states plus Washington, D.C.).

    Confirmed with our clinical network's licensing and routing team, 2026-07-24.

From our state-by-state rules tracker — get an email when a rule changes.

Medicaid & insurance in Washington, DC

Limited coverage

DC Medicaid covers GLP-1s for type 2 diabetes with prior authorization. Coverage for weight-management indications is limited. Compounded GLP-1s are not covered.

Pallas is a cash-pay telehealth service. Medicaid and private insurance do not apply to our prescriptions; pricing is flat and disclosed up front.

Simple cash-pay pricing in Washington, DC

No insurance, and the same price in every Washington, DC ZIP code. You see your full price during intake, before you pay anything.

Compounded plans · provider care included

  • Compounded semaglutide injection$139 first month, then $199 every 4 weeks, charged once a clinician prescribes, then until you cancel
  • Compounded tirzepatide injection$179 first month, then $299 every 4 weeks, charged once a clinician prescribes, then until you cancel
  • Compounded semaglutide daily tablet$777 every 12 weeks ($259/mo avg), charged once a clinician prescribes, then until you cancel

Your plan price covers your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free and discreet, only if prescribed; refunded in full if a clinician decides treatment isn’t right for you. Cancel anytime. Pay-over-time options are available at checkout.

See the full Washington, DC cost guide

Brand-name · FDA-approved

FDA-approved Wegovy® (pen or pill), Zepbound® and Foundayo™ for chronic weight management, plus Ozempic® and Mounjaro® for type 2 diabetes, are available cash-pay: the daily Wegovy® pill and Foundayo™ are $299 for your first month, then $499 every 4 weeks; the weekly pens start at $1,069/mo. Your clinician helps determine which option is appropriate for you.

Pallas offers both FDA-approved and compounded medications. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Eligibility and treatment are determined by a US-licensed clinician; results vary. Private pay only (no insurance). Operated by Brentmoor, Inc.

Semaglutide vs tirzepatide in Washington, DC

Both are once-weekly injections available to Washington, DC patients through Pallas, as compounded preparations and as the FDA-approved brand-name products. They work differently: semaglutide activates the GLP-1 receptor, while tirzepatide activates both the GLP-1 and GIP receptors — two of the gut hormones that regulate appetite and fullness.

In SURMOUNT-5, the head-to-head clinical trial of the FDA-approved products, Zepbound® (tirzepatide 10 mg or 15 mg weekly) produced greater average weight loss than Wegovy® (semaglutide 1.7 mg or 2.4 mg weekly) — 20.2% versus 13.7% of body weight over 72 weeks — with broadly similar tolerability. That trial predates Wegovy®'s higher 7.2 mg weekly dose, which reached 18.7% average weight loss over 72 weeks in the separate STEP UP trial; separate trials do not provide a direct comparison. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary.

Cost and track record differ too: compounded semaglutide renews at $199 every 4 weeks versus $299 for tirzepatide (full terms above), and semaglutide has the longer post-market record. Which medication fits your health history, goals, and budget is a decision you make with a clinician licensed in Washington, DC — our full semaglutide vs tirzepatide comparison covers the deeper differences.

Cities served in Washington, DC

Partner pharmacies ship to every ZIP code in Washington, DC, including:

  • Georgetown
  • Capitol Hill
  • Columbia Heights
  • Navy Yard
  • Anacostia
  • Dupont Circle
  • Foggy Bottom
  • Shaw
  • Brookland
  • Petworth

Washington, DC GLP-1 questions

Start Pallas's online intake — it takes about five minutes and covers your health history, goals, and current medications. Because the District of Columbia requires a synchronous visit to establish the provider-patient relationship, a DC-licensed clinician completes that review with a live video visit, scheduled right after your intake, rather than a questionnaire alone. If a GLP-1 is clinically appropriate, your clinician prescribes it, and a US-licensed pharmacy ships your medication to any address in the District, typically within 2–3 business days.

The process is the same as for semaglutide — complete Pallas's online intake, then meet with a DC-licensed clinician over live video, which the District requires before an initial prescription. If appropriate, your clinician can prescribe either compounded tirzepatide, prepared per-patient by a US-licensed §503A pharmacy based on a documented clinical rationale, or an FDA-approved brand-name option like Zepbound® or Mounjaro®, through the same intake. These are distinct products with different regulatory status; your clinician will explain which fits you.

Yes — compounded semaglutide is available to eligible Washington, DC residents through licensed telehealth, after the District's required live video visit. It is prepared per-patient by US-licensed compounding pharmacies under FDCA §503A, and a DC-licensed clinician must prescribe it based on a documented, patient-specific clinical rationale. Pallas serves DC with free shipping. FDA-approved brand-name options like Wegovy® and Zepbound® are also available through the same intake.

Yes. District of Columbia nurse practitioners have full independent practice and prescribing authority under exclusive licensure by the DC Board of Nursing — no collaborative agreement or physician supervision is required (D.C. Code §3-1206.07a). Semaglutide and tirzepatide are not controlled substances, and a DC-licensed nurse practitioner can prescribe them via telehealth once the District's live video visit requirement is met. Every Pallas clinician who treats DC patients holds an active District of Columbia license appropriate to their role.

Several licensed telehealth platforms serve Washington, DC residents seeking compounded semaglutide. Before choosing one, verify that its clinicians are licensed in the District of Columbia, that it works with US-licensed §503A compounding pharmacies, and that it holds LegitScript Healthcare Merchant Certification — you can check any platform's certification status in LegitScript's public database. Pallas serves DC residents.

Yes — District of Columbia Board of Medicine telemedicine rules require a real-time evaluation to establish the provider-patient relationship, so your DC-licensed Pallas provider completes a live video visit right after your online intake. After that first visit, ongoing care — check-ins, dose adjustments, and refills — continues asynchronously by secure message. You never have to travel to a physical office.

Pallas is a cash-pay telehealth service — there is no insurance to bill; DC Medicaid covers GLP-1s for type 2 diabetes with prior authorization but not for weight management, and doesn't cover compounded GLP-1s. Your Pallas Membership covers your clinician's review, ongoing check-ins, and care-team messaging; the medication is billed separately and ships free to your DC address, only when a clinician prescribes it. Most DC patients receive their medication within 2–3 business days of the pharmacy filling the prescription, consistently across every neighborhood — Georgetown, Capitol Hill, Columbia Heights, and everywhere else in the District. You see your full price during intake before you pay anything — no surprise renewal markups. The price is the same whether you are in Georgetown, Columbia Heights, or anywhere else in the District.

Eligibility is always decided by a DC-licensed clinician after your intake and video visit, never by an automated quiz. In general, GLP-1 medications for weight management are considered for adults with a BMI of 30 or higher, or a BMI of 27 or higher together with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. Your clinician also reviews your medical history and current medications to confirm a GLP-1 is appropriate and safe for you, and will tell you if it is not.

Brand-name medications — Wegovy® and Ozempic® (semaglutide) and Zepbound® and Mounjaro® (tirzepatide) — are FDA-approved products from their manufacturers, offered cash-pay. Compounded semaglutide and tirzepatide are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy, when a clinician documents a patient-specific clinical need. While these pharmacies are highly regulated, the compounded medications themselves are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Which option fits you is a clinical decision you make with your DC-licensed provider.

Yes, many patients transfer their care to Pallas. During your video visit you tell your clinician which medication and dose you take now and how you have tolerated it. Your DC-licensed provider reviews that history and, if appropriate, continues you at a comparable dose or adjusts your titration plan. Do not stop or change a prescription on your own — let your clinician guide any transition.

Often, yes. During intake you list every prescription, over-the-counter medication, and supplement you currently take, and your DC-licensed clinician reviews that list for interactions before prescribing. Common medications like metformin, blood pressure medication, and hormonal birth control don't automatically rule you out — your clinician weighs your full history and tells you directly if a GLP-1 isn't appropriate alongside something you're taking.

Most patients use a once-weekly injection with a very fine needle, but a compounded oral semaglutide tablet is available for people who would rather not inject. Both are prescribed only after a clinician confirms they are appropriate for you, and your provider can help you weigh which form fits your routine and goals.

The most common side effects are gastrointestinal — nausea, constipation, diarrhea, or reflux — and they are usually mildest when the dose is raised slowly, which is why clinicians titrate up gradually. GLP-1s are not right for everyone; they are avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2, and during pregnancy. Your Pallas clinician screens for these before prescribing and stays available to help you manage any side effects.

You complete a detailed online intake sharing your health history, goals, and current medications, then meet with a clinician licensed by the District of Columbia Board of Medicine over live video — the District requires this real-time visit to establish your provider relationship. After that first visit, most ongoing care, including check-ins, dose adjustments, and refill questions, can be handled asynchronously by secure message. If a GLP-1 is appropriate, your prescription goes to a licensed pharmacy that ships to any address in the District, usually within 2–3 business days.

After your DC-licensed clinician approves your prescription, your first shipment ships to your address and most patients start on a low dose that's titrated up gradually to help minimize side effects like nausea. Your care team checks in by secure message during the first few weeks to see how you're tolerating the medication, and your clinician can adjust your dose directly in the app if needed — a separate visit usually isn't required. You can message your care team with questions at any point.

Pallas care is ongoing, not a one-time script. Your plan renews on a regular cadence so your medication arrives before you run out, and your clinician schedules check-ins to monitor your response, adjust your dose, and manage side effects. You can message your care team from the Pallas app or your patient portal, and change your plan or cancel anytime from the portal — no phone calls or retention hoops.

Compounded semaglutide injection through Pallas is $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Washington, DC address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Compounded tirzepatide injection through Pallas is $179 first month, then $299 every 4 weeks, charged once a clinician prescribes. Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Washington, DC address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Yes. FDA-approved Wegovy® (pen or pill), Zepbound® and Foundayo™ for chronic weight management — plus Ozempic® and Mounjaro® for type 2 diabetes — are available to Washington, DC patients cash-pay: the daily Wegovy® pill and Foundayo™ are $299 for your first month, then $499 every 4 weeks, and the weekly pens start at $1,069/mo; insurance is not billed. Whether a brand-name or compounded medication is appropriate for you is determined by a clinician licensed in Washington, DC during intake.

Coverage of GLP-1 medications for weight loss through Medicaid is limited. DC Medicaid covers GLP-1s for type 2 diabetes with prior authorization. Coverage for weight-management indications is limited. Compounded GLP-1s are not covered. Pallas is a cash-pay telehealth service — we do not bill Medicaid or private insurance. Pricing is flat and disclosed up front; the cost questions on this page carry current plan terms.

You have two cash-pay paths in Washington, DC, and neither requires insurance. One: stay on FDA-approved Wegovy® or Zepbound® at flat cash-pay pricing from $1,069/mo. Two: if a clinician licensed in Washington, DC determines it is clinically appropriate for you, a compounded semaglutide plan ($139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime.) or compounded tirzepatide plan ($179 first month, then $299 every 4 weeks, charged once a clinician prescribes. Cancel anytime.), prepared per-patient by a US-licensed pharmacy under FDCA §503A. There is no gap in care: start the online intake, tell your clinician what you take now and your current dose, and they factor that history into your treatment plan and starting dose. Our guide to switching GLP-1 telehealth providers on the Pallas blog covers records, timing, and what to expect.

That is a decision you make with your clinician. Semaglutide activates the GLP-1 receptor; tirzepatide activates both the GLP-1 and GIP receptors. In the SURMOUNT-5 head-to-head trial of the FDA-approved products, Zepbound® (tirzepatide 10 mg or 15 mg weekly) produced greater average weight loss than Wegovy® (semaglutide 1.7 mg or 2.4 mg weekly) — 20.2% versus 13.7% of body weight over 72 weeks. Wegovy®'s maximum dose is now 7.2 mg weekly, which was not studied in SURMOUNT-5; in the separate STEP UP trial it reached 18.7% average weight loss over 72 weeks. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary. Semaglutide plans cost less and semaglutide has the longer post-market record; a clinician licensed in Washington, DC weighs your history, goals, and budget to recommend a starting point.

It depends on what you are comparing. Pallas is a cash-pay telehealth service that serves every ZIP code in Washington, DC with one all-in plan price for compounded semaglutide: $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. There is no separate membership fee, and nothing is charged until a clinician prescribes. Washington, DC requires one live video visit, which is included. Before paying any service, check whether the quoted price includes the medication or is a membership billed on top of it, whether the company is LegitScript-certified, and whether you are charged before a clinician has prescribed.

Start your Washington, DC intake

Under 5 minutes. Reviewed by a clinician licensed in Washington, DC.

Start intake